Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, scheduled to enter Phase 1 clinical trials in the second half of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 2 study of RDEA806 in HIV-infected patients and initiating clinical studies on three additional comp
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NasdaqGS: ABAX ), a medical products ... results for the first fiscal quarter ended June 30, ... of $47.5 million, up 10% over last year,s comparable ... over last year,s comparable quarter. Revenues highlights: ... 20% over last year,s comparable quarter. , Veterinary ...
(Date:7/24/2014)... THOUSAND OAKS, Calif. , July 24, 2014 ... will report its second quarter financial results on Tuesday, July ... The announcement will be followed by a conference call with ... call from Amgen will be Robert A. Bradway , ... senior management team. Live audio of the conference ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... Calif., March 19, 2012 diaDexus, Inc. (OTC Bulletin ... proprietary cardiovascular diagnostic products, today highlighted data from two ... Test for Lp-PLA(2)  Activity.  The PLAC® Test for Lp-PLA(2) ... States and is an investigational assay in the United ...
... 2012  Nouveau Life Pharmaceuticals, soon to be changed from ... announced today that Advent Financial, a leading financial analyst ... 5-year revenue for the Company at $42MM.  Advent has ... experience at large investment banks including Bank of America, ...
Cached Medicine Technology:diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 2diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 3diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 4diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 5diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay 6Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM 2
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... New York, NY (PRWEB) July 25, 2014 ... cut ticket prices across the board for the Guinness ... Liverpool FC and Olympiacos FC at Soldier Field ... is also offering their customer appreciation promo/coupon/offer code SOCCER-2014 ... be an amazing year for diehard soccer fans in ...
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
Breaking Medicine News(10 mins):Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3
... WuXi PharmaTech (Cayman) Inc.,(NYSE: WX ), a ... and medical device industries, with operations,in China and the ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ... 2009 Net Revenues Increase 5% Year Over Year to, ...
... Hundreds of Grass-Roots Activists and Scientific Leaders Meet in Nashville for Al ... ... -- The Climate Project (TCP), an international non-profit founded by former Vice ... climate crisis at a grassroots level worldwide, is opening its North American ...
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today announced that its Board of Directors declared a ... $0.10 per share, payable on July 20, 2009, to ... Diagnostics , Quest Diagnostics is the world,s leading ...
... MDAs policymakers consider ways to cut health costs as ... of physician practices finds that physicians on average are ... administrative tasks required by health plans. According to ... Weill Cornell Medical College and colleagues, physician practices report ...
... Health Systems, ,party philanthropy, and a caring young girl ... King Cardiac Foundation (LKCF), founded by internationally acclaimed ... its goal to Save a Heart a Day ... have received life saving cardiac treatment from the Foundation ...
... Corporation announced today that it has entered into a multi-year, sole-source ... in infant formulas and growing-up milks produced by Lactalis and sold ... ... May 14, 2009 - Martek Biosciences Corporation (NASDAQ: MATK) ...
Cached Medicine News:Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 2Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 3Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 4Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 5Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 6Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 7Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 8Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 9Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 10Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 11Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 12Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 13Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 14Health News:WuXi PharmaTech Announces First-Quarter 2009 Results 15Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 2Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 3Health News:The Climate Project Brings Together Historic Gathering of World's Experts on Climate Change 4Health News:Physician practice interactions with health plans cost $31 billion a year 2Health News:Physician practice interactions with health plans cost $31 billion a year 3Health News:The Larry King Cardiac Foundation Achieves Record Life-Saving Pace With Help From New Friends and Partners 2Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 2Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid STR, a microbial identification system....
Medicine Products: